Cell Kinetics Osake

Cell Kinetics EBITDA

Delisted

EBITDA (Tulos ennen korkoja, veroja ja poistoja) yhtiöstä Cell Kinetics (CKNTF) 21.7.2026 päivämäärällä on −2,40 M USD.

EBITDA

−2,40 MUSD

Viimeksi päivitetty:

EBITDA (Tulos ennen korkoja, veroja ja poistoja) yhtiöstä Cell Kinetics on 2026 −2,40 M USD. EBITDA (Tulos ennen korkoja, veroja ja poistoja) yhtiöstä Cell Kinetics oli 2025 - USD. Se laskee % matalampi edelliseen vuoteen verrattuna.
Access this data via the Eulerpool API

Cell Kinetics Osakeanalyysi

Mitä Cell Kinetics tekee? Cell Kinetics Ltd is a company specializing in the research and production of cell therapy products. The company was founded in 2020 and is based in London, United Kingdom. Cell Kinetics Ltd has a visionary mission that inspires the company to discover and develop groundbreaking solutions to improve people's health and well-being. The company aims to research, develop, and deliver therapies for serious diseases such as cancer and neurodegenerative disorders. The business model of Cell Kinetics Ltd is based on comprehensive research of new cell therapies and collaboration with academic partners to validate the clinical benefits of these therapies. The company has established partnerships with leading academic institutions and medical centers in Europe and the USA. Cell Kinetics Ltd works in various areas to achieve the goal of discovering and developing new therapies for serious diseases. An important focus of the company is the development of cell culture methods for the production and maintenance of therapeutic cells in large quantities. The company has extensive experience in developing artificial platforms for cell cultivation, including bioreactor-based cultivation, single-cell-sensitive cultivation, and the use of chemicals for cell cultivation. Another focus of Cell Kinetics Ltd is the development of carcinoma therapies. The company has developed a special technology for the production of T-cells that can be used to kill cancer cells. These T-cells are obtained from blood samples of cancer patients and cultivated in vitro. The company has also developed a technology that allows these T-cells to be modified to fight deadly diseases such as leukemia and lymphoma. Another focus of Cell Kinetics Ltd is the development of therapies for neurodegenerative diseases such as Alzheimer's and Parkinson's. The company is developing special technologies to differentiate neural stem cells that can serve as a therapeutic tool for the treatment of these diseases. These neural stem cells can be used to repair damaged nerve cells. Cell Kinetics Ltd is proud to offer a range of products that can contribute to improving the health and well-being of patients. The company offers therapy products for cancer treatment, neurodegenerative diseases, and cardiovascular diseases, among others. In addition, the company also provides a wide range of services, including the development and production of cell therapy products, as well as artificial platforms for cell cultivation. Overall, Cell Kinetics Ltd has become a major player in the field of cell therapy and the development of therapies for serious diseases. The company is committed to continuing to develop groundbreaking discoveries and technologies to improve the lives of millions of people around the world. Cell Kinetics on yksi Eurpooliin suosituimmista yhtiöistä.

Usein kysytyt kysymykset Cell Kinetics osakkeesta

Yhtiön Cell Kinetics EBITDA (Tulos ennen korkoja, veroja ja poistoja) on −2,40 M USD vuonna 2026.

Access this data via the Eulerpool API

Tuloslaskelma — Cell Kinetics

Kaikki tunnusluvut — Cell Kinetics